Novo Nordisk Shares Fall After U.S. Policy Signals Drug Price Cuts
Source: coincentral.com Key Points: U.S. plans drug price cuts, targeting Ozempic and similar drugs under a new pricing model. Novo Nordisk shares fell 6.3%, with Eli Lilly and Zealand Pharma also down. Company in talks with U.S. officials; analysts expect limited financial impact. COPENHAGEN, Oct. 17—Novo Nordisk shares declined as much as 6.4% on Friday after the U.S. administration signaled that prices for certain weight-loss and diabetes drugs may be reduced under a proposed national pricing framework. The policy, discussed during a White House event on fertility treatments and prescription costs, aims to narrow the gap between U.S. and international drug prices. Under the proposed “most favored nation” model, drugmakers would be required to align U.S. prices with those charged in other developed nations. During the event, the President identified Novo Nordisk’s Ozempic as one of the drugs potentially affected by the new pricing structure. Ozempic, primarily approved for diab...